Related Experiment Video
Updated: Dec 14, 2025
Induction and Assessment of Exertional Skeletal Muscle Damage in Humans
Published on: December 11, 2016
Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
Dimitrios Daoussis1, Konstantinos Melissaropoulos2, Theodoros Dimitroulas3
1Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece.
Background:
Immune checkpoint inhibitors (ICI) are anti-cancer drugs that act by enhancing anti-tumour immunity. Due to their mechanism of action, they have been associated with immune related adverse events (Ir-AE), including musculoskeletal manifestations.
Aim:
To assess a) the prevalence, clinical and imaging (MRI) characteristics of ICI-induced musculoskeletal immune related adverse events (ir-AE) in a prospective manner, b) the potential association of musculoskeletal ir-AE with oncologic response and changes in the immune system at the level of soluble molecules (cytokines) as well as T/B cell subpopulations.
Methods:
This a multicentre prospective study. We plan to recruit all patients who are going to start treatment with ICI from October 2019 until October 2020 in all collaborating Oncology Departments. This study is consisted of a clinical and a laboratory arm.
Results:
The study is currently recruiting patients.
Conclusions:
We anticipate that this study will provide useful data regarding the clinical characteristics of ICI-induced musculoskeletal manifestations as well as potential predictive biomarkers.
